DOI: 10.24075/brsmu.2018.094

OPINION

The use of monoclonal antibodies in autoimmunity treatment

About authors

1 Group of structural Organization of T-cell Immunity, Department of Adaptive Immunity Genomics, Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Moscow

2 Department of Molecular Technologies, Institute of Translational Medicine, Pirogov Russian National Research Medical University, Moscow

Correspondence should be addressed: Ekaterina M. Merzlyak
Miklouho-Maclay 16/10, Moscow, 117997; ur.liam@99niretake

About paper

Funding: this work was supported by the Ministry of Science and Higher Education of the Russian Federation (ID RFMEFI60716X0158).

Received: 2018-12-06 Accepted: 2018-12-27 Published online: 31.12.2018
|

Recently, monoclonal antibodies (MA) have gained popularity as therapeutic agents for the treatment of autoimmune disorders. These antibodies target proinflammatory cytokines, as well as T and B cells potentially involved in the pathogenesis of such conditions. In the present work we attempt to give a systematic description of available therapeutic MA, highlight their key mechanisms of action and pinpoint their adverse effects. We believe that MA that are capable of recognizing and eliminating pathogenic T- and B-cell clones hold the most promise for medical application as biologics. Detection and identification of autoreactive lymphocyte clones is one of the most serious challenges of contemporary medicine.

Keywords: therapeutic antibody, autoimmunity treatment, autoimmune diseases, monoclonal antibody

КОММЕНТАРИИ (0)